全球心絞痛藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

全球心絞痛藥物市場需求預計將從 2023 年的 116.9 億美元達到 2032 年近 162.5 億美元的市場規模，2024-2032 年研究期間複合年成長率為 3.73%。

心絞痛藥物是用於緩解和控制與心絞痛相關的胸痛的藥物，心絞痛是一種由心肌血流量減少引起的疾病。這些藥物的常見類別包括硝酸鹽（例如，硝酸甘油）、BETA-受體阻斷劑（例如，美托洛爾）、鈣通道阻斷劑（例如，氨氯地平）和抗血小板藥物（例如，阿斯匹靈).這些藥物的作用是擴張血管、降低心臟工作負荷和防止血栓，進而改善心臟的氧氣輸送。使用這些藥物有效治療心絞痛有助於降低心絞痛發作的頻率和嚴重程度，提高生活品質，並預防心臟病等併發症。

市場動態

心血管疾病盛行率的激增導致心絞痛的發生率更高，因此對有效的心絞痛藥物的需求更大。藥物研究的進步導致了新的和改進的心絞痛藥物的開發，這些藥物具有更好的療效和安全性，使它們對患者和醫療保健提供者更具吸引力。此外，全球人口老化，更容易罹患心血管疾病，顯著增加了對這些藥物的需求。患者和醫療保健提供者對心絞痛早期診斷和治療重要性的認知不斷增強，進一步推動了市場成長。此外，旨在降低心血管疾病負擔的支持性政府措施和醫療保健政策在市場成長中發揮著不可或缺的作用。醫療保健支出的增加和醫療保健基礎設施的擴大，特別是在新興經濟體，提高了心絞痛藥物的可近性和可用性。此外，擴大採用生活方式改變和預防措施來管理和降低心血管疾病的風險，也增加了對這些藥物的需求。然而，高成本和潛在的副作用可能會挑戰未來幾年的市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球心絞痛藥物市場的各個細分市場進行了包容性評估。心絞痛藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

心絞痛藥物市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按治療類別

• BETA受體阻斷劑
• 鈣拮抗劑
• 抗凝血劑
• 抗血小板
• 其他（硝酸鹽、抗心絞痛藥（雷諾嗪）、ACE 抑制劑）'

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲心絞痛藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。心絞痛藥物市場的主要參與者包括安進公司、賽諾菲公司、吉利德科學公司、阿斯特捷利康公司、葛蘭素史克公司、禮來公司、輝瑞公司、諾華公司、XyloCor Therapeutics Inc.、天士力製藥公司本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來能力、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法論
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：心絞痛藥物 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 按治療類別分類的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球心絞痛藥物市場分析：依治療類別

• 按治療類別概述
• 按治療類別進行歷史和預測數據分析
• BETA受體阻斷劑
• 鈣拮抗劑
• 抗凝血劑
• 抗血小板
• 其他（硝酸鹽、抗心絞痛藥（雷諾嗪）、ACE 抑制劑）'

第 6 章：全球心絞痛藥物市場分析：依地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區按國家銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲按國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 7 章：心絞痛藥廠的競爭格局

• 心絞痛藥物市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 8 章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• Amgen Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Sanofi SA
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Gilead Sciences Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• AstraZeneca Plc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• GlaxoSmithKline Plc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Eli Lilly And Company
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Pfizer Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Novartis AG
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• XyloCor Therapeutics Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Tasly Pharmaceuticals Inc
• 公司簡介
• 公司收入
• 產品
• 最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

The global demand for Angina Pectoris Drugs Market is presumed to reach the market size of nearly USD 16.25 Billion by 2032 from USD 11.69 Billion in 2023 with a CAGR of 3.73% under the study period 2024-2032.

Angina pectoris drugs are medications used to relieve and manage the chest pain associated with angina, a disorder caused by reduced blood flow to the heart muscle. Common classes of these drugs include nitrates (e.g., nitroglycerin), beta-blockers (e.g., metoprolol), calcium channel blockers (e.g., amlodipine), and antiplatelet agents (e.g., aspirin). These medications work by dilating blood vessels, lowering heart workload, and preventing blood clots, thereby improving oxygen delivery to the heart. Effective management of angina pectoris with these drugs helps lower the frequency and severity of angina attacks, improve quality of life, and prevent complications such as heart attacks.

MARKET DYNAMICS

The proliferating prevalence of cardiovascular diseases leads to a higher incidence of angina pectoris and, consequently, a greater demand for effective angina pectoris drugs. Advances in pharmaceutical research have resulted in the development of new and improved angina pectoris drugs that offer better efficacy and safety profiles, making them more appealing to patients & healthcare providers. Additionally, the aging global population, which is more prone to cardiovascular conditions, significantly boosts the demand for these medications. The growing awareness about the significance of early diagnosis and management of angina pectoris among patients and healthcare providers further drives market growth. Moreover, supportive government initiatives & healthcare policies aimed at lowering the burden of cardiovascular diseases play an integral role in market growth. Increased healthcare expenditure and expanding healthcare infrastructure, particularly in emerging economies, enhance the accessibility and availability of angina pectoris drugs. Furthermore, the rising adoption of lifestyle changes & preventive measures to manage and lower the risk of cardiovascular diseases also contributes to the demand for these drugs. However, high costs and potential side effects may challenge market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Angina Pectoris Drugs. The growth and trends of Angina Pectoris Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Angina Pectoris Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapeutic Class

• Beta Blockers
• Calcium Antagonists
• Anticoagulants
• Anti-Platelets
• Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)'

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Angina Pectoris Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Angina Pectoris Drugs market include Amgen Inc., Sanofi S.A., Gilead Sciences Inc., AstraZeneca Plc., GlaxoSmithKline Plc., Eli Lilly And Company, Pfizer Inc., Novartis AG, XyloCor Therapeutics Inc., Tasly Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ANGINA PECTORIS DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutic Class
  • 3.7.2 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANGINA PECTORIS DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS

• 5.1. Overview By Therapeutic Class
• 5.2. Historical and Forecast Data Analysis By Therapeutic Class
• 5.3. Beta Blockers Historic and Forecast Sales By Regions
• 5.4. Calcium Antagonists Historic and Forecast Sales By Regions
• 5.5. Anticoagulants Historic and Forecast Sales By Regions
• 5.6. Anti-Platelets Historic and Forecast Sales By Regions
• 5.7. Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)' Historic and Forecast Sales By Regions

6. GLOBAL ANGINA PECTORIS DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 6.1. Regional Outlook
• 6.2. Introduction
• 6.3. North America Sales Analysis
  • 6.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.3.2 North America By Segment Sales Analysis
  • 6.3.3 North America By Country Sales Analysis
  • 6.3.4 United States Sales Analysis
  • 6.3.5 Canada Sales Analysis
  • 6.3.6 Mexico Sales Analysis
• 6.4. Europe Sales Analysis
  • 6.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.4.2 Europe By Segment Sales Analysis
  • 6.4.3 Europe By Country Sales Analysis
  • 6.4.4 United Kingdom Sales Analysis
  • 6.4.5 France Sales Analysis
  • 6.4.6 Germany Sales Analysis
  • 6.4.7 Italy Sales Analysis
  • 6.4.8 Russia Sales Analysis
  • 6.4.9 Rest Of Europe Sales Analysis
• 6.5. Asia Pacific Sales Analysis
  • 6.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.5.2 Asia Pacific By Segment Sales Analysis
  • 6.5.3 Asia Pacific By Country Sales Analysis
  • 6.5.4 China Sales Analysis
  • 6.5.5 India Sales Analysis
  • 6.5.6 Japan Sales Analysis
  • 6.5.7 South Korea Sales Analysis
  • 6.5.8 Australia Sales Analysis
  • 6.5.9 South East Asia Sales Analysis
  • 6.5.10 Rest Of Asia Pacific Sales Analysis
• 6.6. Latin America Sales Analysis
  • 6.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.6.2 Latin America By Segment Sales Analysis
  • 6.6.3 Latin America By Country Sales Analysis
  • 6.6.4 Brazil Sales Analysis
  • 6.6.5 Argentina Sales Analysis
  • 6.6.6 Peru Sales Analysis
  • 6.6.7 Chile Sales Analysis
  • 6.6.8 Rest of Latin America Sales Analysis
• 6.7. Middle East & Africa Sales Analysis
  • 6.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.7.2 Middle East & Africa By Segment Sales Analysis
  • 6.7.3 Middle East & Africa By Country Sales Analysis
  • 6.7.4 Saudi Arabia Sales Analysis
  • 6.7.5 UAE Sales Analysis
  • 6.7.6 Israel Sales Analysis
  • 6.7.7 South Africa Sales Analysis
  • 6.7.8 Rest Of Middle East And Africa Sales Analysis

7. COMPETITIVE LANDSCAPE OF THE ANGINA PECTORIS DRUGS COMPANIES

• 7.1. Angina Pectoris Drugs Market Competition
• 7.2. Partnership/Collaboration/Agreement
• 7.3. Merger And Acquisitions
• 7.4. New Product Launch
• 7.5. Other Developments

8. COMPANY PROFILES OF ANGINA PECTORIS DRUGS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Market Concentration Rate
• 8.3. Amgen Inc.
  • 8.3.1 Company Overview
  • 8.3.2 Company Revenue
  • 8.3.3 Products
  • 8.3.4 Recent Developments
• 8.4. Sanofi S.A.
  • 8.4.1 Company Overview
  • 8.4.2 Company Revenue
  • 8.4.3 Products
  • 8.4.4 Recent Developments
• 8.5. Gilead Sciences Inc.
  • 8.5.1 Company Overview
  • 8.5.2 Company Revenue
  • 8.5.3 Products
  • 8.5.4 Recent Developments
• 8.6. AstraZeneca Plc.
  • 8.6.1 Company Overview
  • 8.6.2 Company Revenue
  • 8.6.3 Products
  • 8.6.4 Recent Developments
• 8.7. GlaxoSmithKline Plc.
  • 8.7.1 Company Overview
  • 8.7.2 Company Revenue
  • 8.7.3 Products
  • 8.7.4 Recent Developments
• 8.8. Eli Lilly And Company
  • 8.8.1 Company Overview
  • 8.8.2 Company Revenue
  • 8.8.3 Products
  • 8.8.4 Recent Developments
• 8.9. Pfizer Inc.
  • 8.9.1 Company Overview
  • 8.9.2 Company Revenue
  • 8.9.3 Products
  • 8.9.4 Recent Developments
• 8.10. Novartis AG
  • 8.10.1 Company Overview
  • 8.10.2 Company Revenue
  • 8.10.3 Products
  • 8.10.4 Recent Developments
• 8.11. XyloCor Therapeutics Inc.
  • 8.11.1 Company Overview
  • 8.11.2 Company Revenue
  • 8.11.3 Products
  • 8.11.4 Recent Developments
• 8.12. Tasly Pharmaceuticals Inc
  • 8.12.1 Company Overview
  • 8.12.2 Company Revenue
  • 8.12.3 Products
  • 8.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Therapeutic Class (USD MN)
• Beta Blockers Market Sales By Geography (USD MN)
• Calcium Antagonists Market Sales By Geography (USD MN)
• Anticoagulants Market Sales By Geography (USD MN)
• Anti-Platelets Market Sales By Geography (USD MN)
• Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)' Market Sales By Geography (USD MN)
• Global Angina Pectoris Drugs Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Angina Pectoris Drugs Report
• Market Research Process
• Market Research Methodology
• Global Angina Pectoris Drugs Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Therapeutic Class
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Therapeutic Class (USD MN)
• Beta Blockers Market Sales By Geography (USD MN)
• Calcium Antagonists Market Sales By Geography (USD MN)
• Anticoagulants Market Sales By Geography (USD MN)
• Anti-Platelets Market Sales By Geography (USD MN)
• Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)' Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.